MONDAY, April 16 (HealthDay News) -- An experimental drug, ONO-4641, which is an oral sphingosine-1-phosphate receptor agonist, reduces the number of brain lesions in patients with relapsing-remitting multiple sclerosis (MS), according to a study presented at the annual meeting of the American Academy of Neurology, held from April 21 to 28 in New Orleans.
As part of a Phase 2 trial, Timothy Vollmer, M.D., from the University of Colorado in Denver, and colleagues randomly assigned 407 patients with relapsing-remitting MS to placebo or one of three doses of ONO-4641 (0.05 mg, 0.10 mg, or 0.15 mg) once a day for 26 weeks. Participants were aged 18 to 55 years and had Expanded Disability Status Scale scores up to 5.5.
Based on brain scans performed every four weeks starting at week 10, the researchers found that, compared with placebo, there was a reduction in gadolinium-enhancing lesions of 82 percent for the 0.05 mg dose, 92 percent for the 0.10 mg dose, and 77 percent for the 0.15 mg dose. Adverse events appeared to be dose related and included cardiovascular events, liver enzyme elevations, and grade 4 lymphopenia.
"ONO-4641 demonstrated statistically significant efficacy on key end points, compared to placebo, and was well tolerated in patients with relapsing-remitting MS," Vollmer and colleagues conclude.
The study was supported by Ono Pharmaceutical Co., Ltd., which developed ONO-4641.
Copyright © 2012 HealthDay. All rights reserved.
|Previous: Fast Food Salt Levels Vary Among Six Countries||Next: Gender, BMI Impact Bladder Perforation During Resection|
Reader comments on this article are listed below. Review our comments policy.
Submit your opinion:
Are you a Doctor, Pharmacist, PA or a Nurse?
Join the Doctors Lounge online medical community